Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Nebulized Revefenacin and Formoterol in COPD
NCT03573817Phase 3Completed
- Sponsor
- Mylan
- Start
- May 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Revefenacin + Formoterol with Placebo + Formoterol (2 arms). Primary endpoints: Treatment-Emergent Adverse Events, Serious Treatment-Emergent Adverse Events and 3 more. Started May 2018; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03573817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573817.